Biolegend, 302630, Brilliant Violet 421™ anti-human CD25 Antibody, 100tests

CD25 is a 55 kD type I transmembrane glycoprotein also known as the low affinity IL-2 receptor α chain or Tac. It is expressed on progenitor lymphocytes, activated T and B cells, and activated monocytes/macrophages. CD25 is also expressed on a subset of non-stimulated CD4 + T cells termed T regulatory cells. CD25 associates with the IL-2 receptor β (CD122) and common γ chains (CD132) to form the high affinity IL-2R complex.
100tests
Verified Reactivity: Human
Reported Reactivity: Baboon, Chimpanzee, Cynomolgus, Pigtailed Macaque, Rhesus
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Additional reported applications include: immunocytochemistry3.
Additional Product Notes: View more applications data for this product in our Scientific Poster Library.
Application References(PubMed link indicates BioLegend citation): Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed Ernst CW, et al. 2007. Clin. Exp. Immunol. 148:271. (ICC) PubMed
Product Citations: Zhang C, et al. 2023. Front Immunol. 14:1182409. PubMed Ellis GI, et al. 2022. Cell Rep Med. 3:100614. PubMed Ringelstein-Harlev S, et al. 2023. Eur J Haematol. 110:371. PubMed Hsiao CC, et al. 2023. iScience. 26:105785. PubMed Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed Shoda H, et al. 2017. Arthritis Research & Therapy . 10.1186/s13075-017-1308-y. PubMed Nagafuchi Y, et al. 2016. Sci Rep. 6:29338. PubMed van der Heiden M, et al. 2020. Scand J Immunol. e13005:. PubMed Nesspor TC, et al. 2020. Sci Rep. 10:7557. PubMed Huang C, et al. 2020. Theranostics. 10:10498. PubMed Pan YG, et al. 2021. Immunity. 54(6):1245-1256.e5. PubMed Torres-Ruiz J, et al. 2021. Front Immunol. 12:689966. PubMed Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed Lam AJ, et al. 2021. Cell Reports. 36(5):109494. PubMed Jürchott K, et al. 2016. PLoS One. 11: 0150812. PubMed , et al. 2021. Eur J Immunol. 51:2708. PubMed Pagel J, et al. 2020. Front Immunol. 11:565257. PubMed Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed Yang L, et al. 2020. Genes Dis. 7:128. PubMed Ellis GI, et al. 2022. STAR Protoc. 3:101784. PubMed Nowak A, et al. 2018. Front Immunol. 0.513194444. PubMed Nakachi S, et al. 2017. Arthritis Research & Therapy . 10.1186/s13075-017-1309-x. PubMed Gao X, et al. 2022. iScience. 25:104911. PubMed Nguyen J, et al. 2021. Mol Syst Biol. 17:e10560. PubMed Paul S, et al. 2021. Sci Transl Med. 13:. PubMed Hernndez DC, et al. 2021. Immunity. :. PubMed Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed Pandya J, et al. 2016. J Leukoc Biol. 100: 823 - 833. PubMed Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed Li H, et al. 2020. Front Oncol. 1.477083333. PubMed Nowatzky J, et al. 2020. J Vis Exp. . PubMed Fu J, et al. 2021. J Clin Invest. 131:. PubMed Lin-Shiao E, et al. 2022. Nucleic Acids Res. 50:1256. PubMed
RRID: AB_10896914 (BioLegend Cat. No. 302629) AB_11126749 (BioLegend Cat. No. 302630)
Structure: Type I transmembrane glycoprotein, 55 kD
Distribution: Activated T cells and B cells, monocytes/macrophages, Treg
Function: Associates with IL-2 receptor β (CD122) and γ chains (CD132) to form high affinity IL-2R complex
Ligand/Receptor: IL-2
Cell Type: B cells, Macrophages, Monocytes, T cells, Tregs
Biology Area: Cell Biology, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family: CD Molecules, Cytokine/Chemokine Receptors
Antigen References: 1. Taniguchi T, et al. 1993. Cell 73:5. 2. Waldmann T. 1991. J. Biol. Chem. 266:2681.
Gene ID: 3559
UniProt: View information about CD25 on UniProt.org
Clone: BC96
Regulatory Status: RUO
Workshop: V T-072
Other Names: Low affinity IL-2R, IL-2R α chain, Tac, p55
Isotype: Mouse IgG1, κ
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.